Lilly commits up to $1.1 billion to Hong Kong biotech METiS TechBio's AI-driven lipid nanoparticle platform

Lilly announced a partnership with Hong Kong‑listed METiS TechBio, providing an upfront payment in the low double‑digit‑million‑dollar range and making the company eligible for up to $1.1 billion in development, regulatory and commercial milestones, plus tiered royalties on any resulting products.

METiS TechBio's AiLNP platform leverages machine‑learning models to design and optimize ionizable lipids that form lipid nanoparticles (LNPs). The AI‑driven approach aims to improve tissue specificity, potentially boosting the therapeutic performance of drugs delivered in these nanocarriers.

The collaboration did not disclose which Lilly drug candidates will be paired with the LNP technology or the disease areas targeted. LNPs have become a common delivery method for nucleic‑acid therapies, protecting molecules from degradation and enabling precise dosing. The deal positions Lilly to expand its delivery capabilities in a rapidly evolving field.